Rebecca Kruse-Jarres, MD, MPH
Associate Professor of Clinical Medicine
Director, Adult Sickle Cell Program
Dr. Kruse-Jarres received a B.S. in Biochemistry from the University of California, Los Angeles (UCLA) in 1994 where she did research in mitochondrial pathways with Dr. Richard Weiss.
Prior and concurrently, Dr. Kruse-Jarres worked as a registered nurse on the surgical wards at UCLA and immediately prior to medical school in the bone marrow transplant unit at Dartmouth Hitchcock Medical Center in New Hampshire.
In 1999, Dr. Kruse-Jarres graduated from Tulane University, School of Medicine. Concurrently, she received a M.P.H. from the Tulane School of Public Health and Tropical Medicine.
After Dr. Kruse-Jarres completed her residency in General Internal Medicine and fellowship in Hematology/Oncology at Tulane University in July 2005, she joined the faculty of Tulane University, Department of Medicine, Section of Hematology/Oncology.
Dr. Kruse-Jarres is board certified in Internal Medicine, Medical Oncology and Hematology and is currently the Assistant Director of the Louisiana Center for Bleeding and Clotting Disorders, as well as the Director of the Adult Sickle Cell Program.
Dr. Kruse-Jarres' research interests focus on treatment of inhibitors in hemophilia and clinical trials in sickle cell disease.
Kruse-Jarres R, Quon D, Schramm W and Dolan G.Management of bleeding disorders in the elderly. Haemophilia 2012;18(Suppl s2):37–45.
Kruse-Jarres R, Fang J, Leissinger CA, Ganapamo F. Reduced production of IFN-γ and LT-α is associated with successful prednisone therapy in patients with acquired hemophilia A: A Pilot Study. Thromb Res. 2011 Nov;128(5):e86-90.
Goldenberg NA, Kruse-Jarres R, Frick N, Pipe SW, Leissinger CA, Kessler CM. Outcomes of mentored, grant-funded fellowship training in haemostasis /thrombosis: findings from a nested case-control survey study. Haemophilia. 2011 Sep 7. doi: 10.1111/j.1365-2516.2011.02626.x. [Epub ahead of print]
Kruse-Jarres R. Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A. Hematology Am Soc Hematol Educ Program. 2011;2011:407-12.
Kruse-Jarres R, Fang J, Leissinger CA, Ganapamo F. Rituximab therapy modulates IFN-gamma and IL-4 gene expression in a patient with acquired haemophilia A. Br J Haematol. 2010 Jan;148(1):176-8.
Kruse-Jarres R, Lavigne-Lissalde G, Mahlangi J. Inhibitor eradication practices in adult patients – results of a global survey. Haemophilia 2010;16(Suppl 4):17P46.
Kruse-Jarres R, Fang J, Leissinger CA, Ganapamo F. Rituximab therapy modulates IFN-gamma and IL-4 gene expression in a patient with acquired haemophilia A. Br J Haematol. 2009 Sep 18. [Epub ahead of print]
Kruse-Jarres R, Barnett B, Leissinger C. Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opin Biol Ther. 2008 Dec;8(12):1885-96.
Barnett B, Kruse-Jarres R, Leissinger CA. Current management of acquired factor VIII inhibitors. Curr Opin Hematol. 2008 Sep;15(5):451-5.
Singleton T, Kruse-Jarres R, Leissinger C. Emergency Department Care for Patients with Hemophilia and von Willebrand Disease. J Emerg Med. 2008 Aug 30. [Epub ahead of print]
Kruse-Jarres R, Moeller-Hadi C, Leissinger C. Inhibitor development and successful immune tolerance in an HIV infected patient with haemophilia A and after immune reconstitution with HAART. Haemophilia 2007:13(6);707-11. in print)
Kruse-Jarres R and Leissinger C. Haemobilia after transjugular liver biopsy in a patient with severe haemophilia. Haemophilia 2005:11; 642–643.
1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 email@example.com